FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> GlaxoSmithKline | drug prices

Inaccurate: GSK launches 50% discount for uninsured

Tools

Editor's Note: A GSK spokesperson has informed FiercePharma that this story is based on an incorrect press release that was published in error. GSK is not offering a 50 percent discount to uninsured patients, but already has prescription assistance plans in place. You can find more information at www.gskforyou.com.

Andrew Witty puts charity to work again. The GlaxoSmithKline CEO, who's already pledged to slash prices for drugs sold in poor countries, now is offering a 50 percent discount on meds for U.S. patients who are uninsured. The discount-card program applies to anyone under 65 who doesn't have insurance, and patients will have access to it until they get employer-sponsored coverage or until health reform takes care of their insurance problems, whichever comes first. No income restrictions apply, either.

Deirdre Connelly, Glaxo's U.S. pharma president, explains, "We feel this is simply the right thing to do, especially in this economy." Apparently, "the right thing to do" has been much on Witty's mind; as you know, he's has been on something of a good-boy binge. He's pledged to disclose payments to doctors and to limit them, too, and also promised to publish info on Glaxo's support for medical societies. Then there was the push for price cuts in poor countries. And now this.

We could point out the many legitimate business reasons behind such initiatives. A discount card could lure patients to Glaxo meds and away from competing products. The poor-country price cuts won't be that costly, analysts say, and the goodwill Glaxo gains probably will outweigh that cost. And on the disclosure side, Glaxo has simply jumped on a bandwagon that was already moving. And if we were completely cynical about it, we could say that all these programs are a calculated effort to burnish the drugmaker's image at a time when pharma isn't the best-liked industry on the planet.

But we'd like to believe that Witty, et al., aren't just focused on the business calculus here. Perhaps Glaxo-the-corporation can't "care" about people, but maybe some of its leaders can--and do. What are your thoughts? Cynical or sentimental? Let us know.

- read the Glaxo's release

Related Articles:
GSK tops rankings on drug access for poor
GSK cuts prices for poor countries
GSK increases disclosure of MD payments


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Comments (1) | Post a comment
More stories about GlaxoSmithKline   drug prices  

Comments

My contact with Andrew Witty was in the ealy 90's when he went to South Africa to lead the local affiliate of Glaxo/GlaxoWellcome ..... and my recollection of him from that period was as a savvy business man, with a ruthless streak.

So my view is that he's a really smart CEO, who is ahead of the game in understanding the conditions that will be imposed on the pharma industry if they don't make the changes themselves. And he's done a great job of using his insights to grab headlines for himself and GSK, and in coming across as a leader who cares ....

But unless he's changed beyond recognition - I am not convinced about him doing this solely because "it's the right thing to do"! And perhaps he should consider extending his largesse to some of the ex-GSK employees who lost their jobs shortly after he took the top job. (Their fate seems to have been overlooked in your article ...?)

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.